| Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis. | 2024 | BMC Cancer |
| Efficacy and safety of anaplastic lymphoma kinase inhibitors for non–small cell lung cancer: a systematic review and network meta-analysis. | 2023 | Thoracic Cancer |
| Comparative efficacy of ALK inhibitors for treatment-naïve ALK-positive advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis. | 2023 | Cancer |
| Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis. | 2023 | Lung Cancer Management |
| Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis. | 2023 | Exploration of Targeted Anti-Tumor Therapy |
| Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: systematic review and network meta-analysis. | 2023 | Lung Cancer |
| A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer. | 2023 | Cancer Medicine |
| Safety and efficacy of alectinib versus crizotinib in alk-positive non-small cell lung cancer: an update meta-analysis. | 2023 | Pakistan Journal of Pharmaceutical Sciences |
| Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. | 2023 | Thoracic Cancer |
| Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer. | 2022 | Cochrane Database of Systematic Reviews |
| A systematic review of companion diagnostic tests by immunohistochemistry for the screening of alectinib-treated patients in ALK-positive non-small cell lung cancer. | 2022 | Diagnostics |
| Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non small cell lung cancer: a systematic review and meta analysis. | 2022 | Investigational New Drugs |
| First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis. | 2022 | Journal of International Medical Research |
| Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. | 2022 | Future Oncology |
| Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis. | 2022 | Journal of Clinical Medicine |
| Crizotinib versus alectinib for the treatment of ALK-positive non-small cell lung cancer: a systematic review and meta-analysis. | 2022 | Chemotherapy |
| Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. | 2022 | Current Medical Research and Opinion |
| ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. | 2022 | BMJ Open |
| Comparison of efficacy and safety of brigatinib in first-line treatments for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer: a systematic review and indirect treatment comparison. | 2022 | Journal of Clinical Medicine |
| First-line anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive lung cancer in Asian populations: systematic review and network meta-analysis. | 2021 | Journal of Clinical Medicine |
| Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. | 2021 | BMC Cancer |
| Crizotinib versus alectinib for the treatment of ALK-positive non-small cell lung cancer: a systematic review and meta-analysis. | 2021 | Chemotherapy |
| Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer. | 2021 | Cancers |
| Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor–naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis. | 2021 | Journal of Chemotherapy |
| Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis. | 2021 | Cancers |
| Comparison of clinical efficacy of alectinib versus crizotinib in ALK-positive non-small cell lung cancer: a meta-analysis. | 2021 | Frontiers in Oncology |
| ALK inhibitor-induced bradycardia: a systematic-review and meta-analysis. | 2021 | Lung Cancer |
| A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. | 2021 | Pharmacological Research |
| Comparison of clinical efficacy of alectinib versus crizotinib in ALK-positive non-small cell lung cancer: a meta-analysis. | 2021 | Frontiers in Oncology |
| Efficacy and safety of first-line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a Bayesian network meta-analysis. | 2021 | Frontiers in Oncology |
| Comparative efficacy of systemic agents for brain metastases from non-small-cell lung cancer with an EGFR mutation/ALK rearrangement: a systematic review and network meta-analysis. | 2021 | Frontiers in Oncology |
| Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: a systematic review and network meta-analysis. | 2020 | Cancers |
| ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. | 2020 | PLoS One |
| Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis. | 2020 | Annals of Palliative Medicine |
| Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. | 2020 | Clinical Drug Investigation |
| Comparative efficacy of targeted therapies in patients with non-small cell lung cancer: a network meta-analysis of clinical trials. | 2020 | Journal of Clinical Medicine |
| Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. | 2020 | Lung Cancer |
| Efficacy of crizotinib, ceritinib, and alectinib in ALK-positive non-small cell lung cancer treatment: a meta-analysis of clinical trials. | 2020 | Cancers |
| Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis | 2020 | Annals of Palliative Medicine |
| Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer. | 2019 | Medicine (Baltimore) |
| ALK inhibitors in the treatment of ALK positive NSCLC. | 2019 | Frontiers in Oncology |
| Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review. | 2019 | Critical Reviews in Oncology/Hematology |
| The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis. | 2019 | Cancer Management and Research |
| The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and meta-analysis. | 2019 | Lung Cancer |
| Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis. | 2019 | Journal of Thoracic Disease |
